BIIB Related Downgrades
-
Goldman Sachs Downgrades Biogen (BIIB) to Neutral, Removes from CL List
-
Elan Corp (ELN) Initiates New Dividend Program; Will Be Tied to Tysabri Performance
-
BofA/Merrill Lynch Downgrades Biogen (BIIB) to Neutral
-
Piper Jaffray Downgrades Biogen (BIIB) to Neutral
-
Oppenheimer Downgrades Biogen (BIIB) to Perform
-
UBS on U.S. Biotechnology - Updating Outlook on Covered Stocks (GILD, AMGN, BIIB, CELG, INCY, IDIX, VRTX, SGEN)
-
UPDATE: UBS Downgrades Biogen (BIIB) to Neutral; Risk/Reward Now Balanced
-
Barclays Initiating Coverage: A Seamless Approach to Biopharmaceuticals
-
RBC Capital Upgrades Biogen (BIIB), Regeneron (REGN) to Outperform, Downgrades Celgene (CELG) to Sector Perform
-
Standpoint Research Downgrades Biogen Idec (BIIB) to Hold
-
First Global Downgrades Biogen Idec (BIIB) to Market Perform
-
BMO Downgrades Biogen (BIIB) to Market Perform
-
Deutsche Bank Downgrades Biogen-IDEC (BIIB) to Hold; Valuation Call
-
Barclays Downgrades Biogen (BIIB) to Underweight
-
Baird Downgrades Biogen Idec (BIIB) On Tysabri, Not Buying Takeover Talk
-
JP Morgan Downgrades Biogen Idec (BIIB) to Neutral
-
BofA Downgrades Biogen (BIIB) to Neutral
-
Piper Jaffray & Co. Downgrades Biogen Idec (BIIB) to Underperform
-
Credit Suisse downgrades Biogen Idec (BIIB) to Underperform
-
UBS downgrades Biogen (BIIB) to Sell
-
BWS Financial downgrades Biogen IDEC (BIIB) to Hold
-
Morgan Stanely Downgrades Biogen Idec (BIIB) to Underweight
-
Lehman Brothers downgrades Biogen Idec (BIIB) to Equal Weight
-
RBC Capital downgrades Biogen (BIIB) to Sector Perform
-
Cowen downgrades Biogen Idec (BIIB) to Neutral
-
Bernstein downgrades Biogen Idec (BIIB) to Underperform
-
CSFB downgrades BIIB to Underperform
-
Thomas Weisel downgrades BIIB to Underperform
-
Citigroup Downgrades BIIB
-
Morgan Stanley Downgraded BIIB
-
Biogen Idec Downgraded by Lehman Bros & Piper Jaffray
-
Deutche Bank Downgraded BIIB to Sell; Lowered 05, 06 Estimates
Back to BIIB Stock Lookup
